Article

jdsupra.com on 2019-01-08 22:26

Looking to 2019 and beyond - accessing the U.S. pharma/biotech market: Considerations for structuring and bridging the valuation gap in life sciences M&A transactions

On November 8, a team of life sciences lawyers from our Washington, D.C., New York, and Beijing offices hosted a seminar in Beijing on the key ...

Hogan Lovells

Related news

Qualified Opportunity Funds: Investment and Structuring Considerations jdsupra.com
California , United States , Switzerland
Profits Interests: Accounting & Valuation Considerations jdsupra.com
California , United States , Switzerland
Top considerations for structuring health care mergers and acquisitions jdsupra.com
California , United States , Switzerland
Tax-Efficient Structuring Considerations for Family Office Management Expenses jdsupra.com
California , United States , Switzerland
Considerations in Accessing Revolving Credit Lines jdsupra.com
California , United States , Switzerland
[Audio] Podcast: Credit Funds: Compliance Considerations for Valuation jdsupra.com
California , United States , Switzerland
Valuation Challenges for Fintechs Highlight Legal Considerations in ‘Down Rounds’jdsupra.com
California , United States , Switzerland
Proactive Due Diligence Considerations for Life Sciences Dealmakers jdsupra.com
California , United States , Switzerland
Important Considerations When Structuring M&A Transactions for Government Contractors: Pre-Transaction Part 1 of a 3-Part Series jdsupra.com
California , United States , Switzerland
Design, Designation and Regulatory: Structuring Considerations and Regulatory Due Diligence in EU Food and Beverage Transactions jdsupra.com
California , United States , Switzerland
ESOP Valuation and Other Considerations in the Age of the Coronavirus jdsupra.com
California , United States , Switzerland
Dodd-Frank Reporting, Derivative Accounting & Valuation Considerations for Wind Farm Owners jdsupra.com
California , United States , Switzerland
California Consumer Privacy Act: The Challenge Ahead – Four Key Considerations For Health And Life Sciences Companies jdsupra.com
United States , Switzerland , California
[Video] COVID-19 Key Securities Law Impacts and Considerations for Public Life Sciences Companies jdsupra.com
California , United States , Switzerland
Action Step Considerations for Life Sciences Companies Amidst the COVID-19 Pandemic jdsupra.com
California , United States , Switzerland
Structuring Opportunity Zone Funds jdsupra.com
California , United States , Switzerland
Life Sciences and Health Care Horizons - 2020 jdsupra.com
California , United States , Switzerland
Collaboration, License and other Commercial Agreements: Key Considerations for Life Sciences Companies in the Age of COVID-19 jdsupra.com
California , United States , Switzerland
[Webinar] Critical Business Considerations for Life Sciences and Medical Device Companies Amid the COVID-19 Pandemic - April 17th, 12:00 pm - 2:00 pm ET jdsupra.com
California , United States , Switzerland
Basic considerations associated with the use of public-private partnerships (P3s) by colleges and universities with a focus on energy/utility P3s jdsupra.com
California , United States , Switzerland